J Korean Neurosurg Soc.  2023 May;66(3):258-262. 10.3340/jkns.2022.0266.

Pharmacological Management of Germinal Matrix-Intraventricular Hemorrhage

• Chung J
• Lee SK
• Cho CS
• Kim YJ
• Ko JH
• Yun JH
• So JS
• Jung IH

• KMID: 2542010
• DOI: http://doi.org/10.3340/jkns.2022.0266

Abstract

Germinal matrix-intraventricular hemorrhage (GM-IVH) is among the devastating neurological complications with mortality and neurodevelopmental disability rates ranging from 14.7% to 44.7% in preterm infants. The medical techniques have improved throughout the years, as the morbidity-free survival rate of very-low-birth-weight infants has increased; however, the neonatal and long-term morbidity rates have not significantly improved. To this date, there is no strong evidence on pharmacological management on GM-IVH, due to the limitation of well-designed randomized controlled studies. However, recombinant human erythropoietin administration in preterm infants seems to be the only effective pharmacological management in limited situations. Hence, further high-quality collaborative research studies are warranted in the future to ensure better outcomes among preterm infants with GM-IVH.

Keyword

Germinal matrix hemorrhage; Cerebral intraventricular hemorrhage; Preterm infant; Erythropoietin

Reference

References

1. Anderson JG, Baer RJ, Partridge JC, Kuppermann M, Franck LS, Rand L, et al. Survival and major morbidity of extremely preterm infants: a population-based study. Pediatrics. 138:e20154434. 2016.

2. Ballabh P. Pathogenesis and prevention of intraventricular hemorrhage. Clin Perinatol. 41:47–67. 2014.

3. Barekatain B, Saraeian S, Farghadani M, Armanian AM, Shahsanaee A, Rouhani E, et al. Effect of vitamin E in prevention of intraventricular hemorrhage in preterm neonates. Int J Prev Med. 9:97. 2018.

4. Bolisetty S, Dhawan A, Abdel-Latif M, Bajuk B, Stack J, Lui K, et al. Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants. Pediatrics. 133:55–62. 2014.

5. Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 4:CD003665. 2003.

6. Davis AS, Hintz SR, Goldstein RF, Ambalavanan N, Bann CM, Stoll BJ, et al. Outcomes of extremely preterm infants following severe intracranial hemorrhage. J Perinatol. 34:203–208. 2014.

7. Egesa WI, Odoch S, Odong RJ, Nakalema G, Asiimwe D, Ekuk E, et al. Germinal matrix-intraventricular hemorrhage: a tale of preterm infants. Int J Pediatr. 2021:6622598. 2021.

8. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 196:147.e1–e8. 2007.

9. Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 122:375–382. 2008.

10. Fauchère JC, Koller BM, Tschopp A, Dame C, Ruegger C, Bucher HU, et al. Safety of early high-dose recombinant erythropoietin for neuroprotection in very preterm infants. J Pediatr. 167:52-57.e1–e3. 2015.

11. Gilard V, Chadie A, Ferracci FX, Brasseur-Daudruy M, Proust F, Marret S, et al. Post hemorrhagic hydrocephalus and neurodevelopmental outcomes in a context of neonatal intraventricular hemorrhage: an institutional experience in 122 preterm children. BMC pediatr. 18:288. 2018.

12. Heuchan AM, Evans N, Henderson Smart DJ, Simpson JM. Perinatal risk factors for major intraventricular haemorrhage in the Australian and New Zealand Neonatal Network, 1995-97. Arch Dis Child Fetal Neonatal Ed. 86:F86–F90. 2002.

13. Hierro-Bujalance C, Infante-Garcia C, Sanchez-Sotano D, Del Marco A, Casado-Revuelta A, Mengual-Gonzalez CM, et al. Erythropoietin improves atrophy, bleeding and cognition in the newborn intraventricular hemorrhage. Front Cell Dev Biol. 8:571258. 2020.

14. Hunt R, Hey E. Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants. Cochrane Database Syst Rev. 1:CD004343. 2010.

15. Inoue H, Ochiai M, Yasuoka K, Tanaka K, Kurata H, Fujiyoshi J, et al. Early mortality and morbidity in infants with birth weight of 500grams or less in Japan. J Pediatr. 190:112–117.e3. 2017.

16. Kadri H, Mawla AA, Kazah J. The incidence, timing, and predisposing factors of germinal matrix and intraventricular hemorrhage (GMH/IVH) in preterm neonates. Childs Nerv Syst. 22:1086–1090. 2006.

17. Larroque B, Bréart G, Kaminski M, Dehan M, André M, Burguet A, et al. Survival of very preterm infants: epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed. 89:F139–F144. 2004.

18. McCrea HJ, Ment LR. The diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate. Clin Perinatol. 35:777–792. vii. 2008.

19. Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. Cochrane Database Syst Rev. 11:CD004863. 2017.

20. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 92:529–534. 1978.

21. Pieper CH, Smith J, Maree D, Pohl FC. Is nCPAP of value in extreme preterms with no access to neonatal intensive care? J Trop Pediatr. 49:148–152. 2003.

22. Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Semin Perinatol. 41:387–391. 2017.

23. Ramenghi LA, Fumagalli M, Groppo M, Consonni D, Gatti L, Bertazzi PA, et al. Germinal matrix hemorrhage: intraventricular hemorrhage in very-low-birth-weight infants: the independent role of inherited thrombophilia. Stroke. 42:1889–1893. 2011.

24. Raybaud C, Ahmad T, Rastegar N, Shroff M, Al Nassar M. The premature brain: developmental and lesional anatomy. Neuroradiology 55 Suppl. 2:23–40. 2013.

25. Schindler T, Koller-Smith L, Lui K, Bajuk B, Bolisetty S; New South Wales and Australian Capital Territory Neonatal Intensive Care Units’ Data Collection. Causes of death in very preterm infants cared for in neonatal intensive care units: a population-based retrospective cohort study. BMC Pediatr. 17:59. 2017.

26. Smit E, Odd D, Whitelaw A. Postnatal phenobarbital for the prevention of intraventricular haemorrhage in preterm infants. Cochrane Database Syst Rev. 2013:CD001691. 2013.

27. Song J, Wang Y, Xu F, Sun H, Zhang X, Xia L, et al. Erythropoietin improves poor outcomes in preterm infants with intraventricular hemorrhage. CNS Drugs. 35:681–690. 2021.

28. Takashima S, Tanaka K. Microangiography and vascular permeability of the subependymal matrix in the premature infant. Can J Neurol Sci. 5:45–50. 1978.

29. Valdez Sandoval P, Hernández Rosales P, Quiñones Hernández DG, Chavana Naranjo EA, García Navarro V. Intraventricular hemorrhage and posthemorrhagic hydrocephalus in preterm infants: diagnosis, classification, and treatment options. Childs Nerv Syst. 35:917–927. 2019.

30. Vinazzer H. Clinical and experimental studies on the action of ethamsylate on haemostasis and on platelet functions. Thrombosis research. 19:783–791. 1980.

31. Volpe JJ. Impaired neurodevelopmental outcome after mild germinal matrix-intraventricular hemorrhage. Pediatrics. 136:1185–1187. 2015.

32. Wimberley PD, Lou HC, Pedersen H, Hejl M, Lassen NA, Friis-Hansen B. Hypertensive peaks in the pathogenesis of intraventricular hemorrhage in the newborn. Abolition by phenobarbitone sedation. Acta Paediatr Scand. 71:537–542. 1982.

33. Wu T, Wang Y, Xiong T, Huang S, Tian T, Tang J, et al. Risk factors for the deterioration of periventricular-intraventricular hemorrhage in preterm infants. Sci Rep. 10:13609. 2020.

34. Yeo KT, Thomas R, Chow SS, Bolisetty S, Haslam R, Tarnow-Mordi W, et al. Improving incidence trends of severe intraventricular haemorrhages in preterm infants <32 weeks gestation: a cohort study. Arch Dis Child Fetal Neonatal Ed. 105:145–150. 2020.